EDAP TMS S.A. (EDAP) Ablatherm-HIFU Demonstrates Long-Term Efficacy and Safety Over Fourteen-Year Period  
2/8/2013 10:35:22 AM

LYON, France, Feb. 8, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today new data demonstrating the safety and long-term efficacy of Ablatherm-HIFU, an ultrasound guided HIFU device for the treatment of localized prostate cancer. The data was electronically published in January 2013 by the British Journal of Urology, International.